Jazz Pharmaceuticals to acquire Actio Biosciences for $1.32B

Jazz Pharmaceuticals to acquire Actio Biosciences for $1.32B
M&A Snapshot: Jazz Pharmaceuticals acquires Chimerix at a 72% premium deal
Jazz Pharmaceuticals to buy global rights to KRAS inhibitor program
Jazz Pharmaceuticals exploring strategic options, including sale - Bloomberg
14.02BUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
USG508711052
CUSIP
472147107
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
63.44
PEG Ratio
0.96
Book Value
74.10
Dividend Share
-
Dividend Yield
-
Earnings Share
3.38
Wall Street Target Price
295.36
EPS Estimate Current Year
15.49
EPS Estimate Next Year
25.20
EPS Estimate Current Quarter
-2.2089
EPS Estimate Next Quarter
6.5779
Most Recent Quarter
-
Revenue TTM
4,601,286,144
Gross Profit TTM
4,203,438,080
EBITDA
1,927,067,008
Profit Margin
20.45%
Return On Assets TTM
6.86%
Return On Equity TTM
22.11%
Revenue Per Share TTM
74.598
Qtly Revenue Growth YOY
15.50%
Diluted Eps TTM
3.38
Qtly Earnings Growth YOY
3.20%
Trailing PE
63.44
Forward PE
9
Price Sales TTM
3.0253
Price Book MRQ
2.9199
Enterprise Value Revenue
3
Enterprise Value EBITDA
10
903.08
3.20%227.40
2.97%965.00
0.55%314.92
0.35%900.30
0.00%139.16
0.00%528.21
-4.77%355.10
-2.26%34.64
-2.01%153.70
-1.47%